The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Cited by
Sorted by citations
Items 801–900 of 1,000
Molecular insights for the tumor suppressor role of SPOP in prostate cancer
Yan, P., Xue, X., Hou, T., Wang, J., Jiang, W., Wang, Z., Inuzuka, H., & Wei, W. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189560 · Cited by 2
Self-citationSQSTM1/p62-mediated PD-L1 biomolecular condensate formation promotes lung tumorigenesis
Lin, Y.-C., Lin, Y.-W., Wang, R.-H., Chang, C.-J., Pang, J.-Y., Hsiao, M.-C., Wang, H.-M., Wu, S.-Y., Chiang, C., & Chao, J. I. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.046 · Cited by 2
Self-citationQin, H., Qi, T., Yao, N., Sheng, W., Deng, J., Qian, J., Wang, D., Zeng, H., Weng, J., Yang, J., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01298-0 · Cited by 2
Wang, H., Shen, T., Yang, S., Zhou, X., Cao, P., Yu, H., He, K., Fu, M., Yu, H., Liu, X., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218446 · Cited by 2
Self-citationMa, C., Ji, X., Huang, W., Guo, S., Wang, L., Wu, X., Zheng, H., & Wang, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00005 · Cited by 2
Zeng, X., Zhu, Y., Xiao, Y., Zh, Z., Chen, X., Wei, D., Huang, C., Liu, K., 石向华, Luo, F., et al. (2026) · Autophagy · doi:10.1080/15548627.2026.2694660 · Cited by 2
Self-citationYang, Y., Zhu, S., Fu, Z., Sun, C., Yang, F., Zeng, T., Hua, Y., Bao, S., Gao, X., Huang, X., et al. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-54 · Cited by 1
Brett, J. O., Herman, P. E., Mayer, E. L., Bardia, A., & Wander, S. A. (2022) · Current Breast Cancer Reports · doi:10.1007/s12609-022-00461-3 · Cited by 2
Gu, H., Li, T., Beeraka, N. M., Zheng, Y., Zhang, X., Song, R., Zhou, R., Wang, X., Sukocheva, O. A., Fan, R., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286414 · Cited by 2
Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1
Zhang, Y., Xiao, T., Wen, M., Shen, L., Du, L., Wei, S., Wu, B., Yu, Y., Wang, S., & OuYang, B. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168500 · Cited by 2
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma
Shi, C., Ju, H., Wu, Y., Ma, X., Zhang, Z., & Ren, G. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00090-z · Cited by 3
RNF26 up-regulates PD-L1 to regulate the cancer immune response in ccRCC
Ren, W., Li, J., ZENG, R., & Zhu, L. (2024) · Biocell · doi:10.32604/biocell.2024.051747 · Cited by 2
FaSTPACE: a fast and scalable tool for peptide alignment and consensus extraction
Kotb, H. M., & Davey, N. E. (2024) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae103 · Cited by 2
CDK4 gene copy number increase and concurrent genetic changes in acral melanoma of a Chinese cohort
Yang, L., Liu, Y., Guo, R., Du, J., Liu, L., Liu, X., Zhao, J., Fang, S., Zhang, X., & Su, J. (2024) · Pathology · doi:10.1016/j.pathol.2024.06.012 · Cited by 2
Zhao, X., Yu, X., Li, W. G., Chen, Z., Niu, T., Weng, X., Wang, L., & Liu, X. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.101043 · Cited by 2
Jiang, S., Lv, X., Ouyang, Z., Chi, H., Zeng, Y., Wang, Y., He, J., Chen, J., Chen, J., An, K., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202407986 · Cited by 2
Zhai, F., Li, Y., Zheng, J., Yan, C., Wang, S., Yang, W., Jin, J., Luo, X., Zhan, Z., Shi, J., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03347-7 · Cited by 3
Self-citationGao, X., Shen, X., Huang, S., & Huang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02127-9 · Cited by 3
Integrating cuproptosis and immunosenescence: A novel therapeutic strategy in cancer treatment
Firouzjaei, A. A., & Aghaee‐Bakhtiari, S. H. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101983 · Cited by 4
Yi, F., Chen, N., Zhao, M., Gu, Z., Yuan, Y. F., Tang, X., & Liu, F. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01193-7 · Cited by 5
O'Connell, S. M., Murphy, D. B., & Kelly, F. (2024) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/mbfvgm4sxy · Cited by 2
Bose, S., Lee, T. Y., Choi, S., Fazlollahi, L., Rasiej, M. J., Schwartz, G. K., & Ingham, M. A. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00550 · Cited by 2
Tsai, C.-L., Tang, Y., Yang, L., Chao, A., Wang, C., Lin, C., & Lai, C. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.05.020 · Cited by 2
Speckle-type POZ adaptor protein (SPOP) and its role in cancer
Ovalle, W. J. M., Sanabria‐Salas, M. C., & Serrano, M. L. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.717 · Cited by 2
Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery
Mengwasser, K. E. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
NOTCH1 drives immune-escape mechanisms in B cell malignanciesPreprint
Mangolini, M., Maiqués-Díaz, A., Charalampopoulou, S., Hartmann, E., Bloehdorn, J., Moore, A., Lu, J., Franklin, V. N. R., Chilamakuri, C. S. R., Moutsoupoulos, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.10.439192 · Cited by 2
Shu, C., Jin, R., Niu, Q., Cicka, D., Doyle, S. P., Wahafu, A., Fan, D., Zheng, X., Du, Y., Ivanov, A. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.460294 · Cited by 2
The relationship between PD-L1 and quiescence in melanocyte stem cell agingPreprint
Palmer, J. W., Villavicencio, K. M., Idris, M. I., Weddle, D., Filipp, F. V., Program, N. C. S., Pavan, W. J., & Harris, M. L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.22.508528 · Cited by 2
Monitoring the Cell Cycle of Tumor Cells in Mouse Models of Human CancerPreprint
Hammond, T., & Sage, J. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041383 · Cited by 3
Alshammary, A. F., Al-Toub, M., Albukhari, T. A., & Filimban, W. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124606123010009 · Cited by 1
Huang, Y., Liu, H., Liu, B., Chen, X., Li, D., Xue, J., Li, N., Zhu, L., Liu, Y., Xiao, J., et al. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01818-6 · Cited by 1
Self-citationLi, Y., Yuan, X., Yin, X., Zheng, D., Shi, F., Liu, D., Hu, L., Shi, X., Wen, N., He, Q., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03068-4 · Cited by 1
Wu, Y., Xu, Z., Kou, Z., Ye, Q., Chen, L., & Gou, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-11043-5 · Cited by 1
TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity
Hao, J., He, J., Hu, H., Zhu, Z., Zhao, X., Wu, X.-Y., Li, L., Ruan, Y., Yang, J., Luo, X., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03517-7 · Cited by 1
Chang, Y., Wu, C.-C., Hsiao, F.-T., Lin, Y.-S., Lai, T., Huang, K.-H., Tang, S., Lee, C., Chou, S., & Hsu, L.-C. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03550-z · Cited by 1
Lu, Y., Chen, Y., Pan, X., Ma, W., Liu, N., Yang, L., Dong, X., Guo, H., Li, D., & Gan, W. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01125-x · Cited by 1
Hu, Y., Tang, L., Kuang, Z., Huang, D., Li, T., Yin, G., Chen, Y., Guo, W., Han, W., & Wang, P. (2025) · Advanced Science · doi:10.1002/advs.202514347 · Cited by 1
SPOP and HAUSP bidirectionally regulate LZTS2 ubiquitination to modulate the Wnt pathway
Deng, Y., Xie, C., Liu, R., Ma, K., Tang, J. B., & Zhou, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08351-z · Cited by 1
Yan, Q., Qingqing, Z., Yu, S., & Zhang, W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2598380 · Cited by 2
Zhang, S., Liu, M., Tan, D., Lv, K., Li, W., Huang, X., Hou, J., Yang, Y., Chen, C., Feng, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116769 · Cited by 1
He, Z., Chen, Z., Wang, L., Hu, Z., Wang, Z., Zhou, J., Zhu, Y., Lyu, Z., Zhang, W., Lin, F., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117682 · Cited by 1
Self-citationXu, M., Tian, S., Xu, H., Xue, X., Zhang, Q., Hu, H., Wu, G., Geng, X., Yu, D., Xu, H., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03648-z · Cited by 1
Xu, D., Li, J., Qiu, L., Lu, F., Gao, X., Miao, Y., & Wang, G. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112395 · Cited by 1
Roscovitine derivative optimization via molecular dynamics reveals potent and selective CDK5 binders
Botta, L., Carotenuto, G., Arcieri, M., Nisio, E. D., Perticaroli, V., Castrignanò, T., Saladino, R., & Negri, R. (2026) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2026.1741100 · Cited by 1
Huang, S., Song, S., Zhang, X., Gao, J. W., Pu, R., Dai, J., Wu, X., Chen, L., Li, Q., Liu, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202515367 · Cited by 1
Regulation of the immune CD155–CD226–TIGIT axis by cyclin D-CDK4/6
Fassl, A., Espinoza, M. P., Butter, D., Kołodziejczyk, A., Seehawer, M., Hill, C. N., Ning, X., Branigan, T. B., Peñailillo, J., Saengboonmee, C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2522872123 · Cited by 1
Xu, X., Cai, C. H., Zhao, R., Xie, J., Liu, H., Xie, B., Lou, J., Wang, H., Wu, X., Han, W., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08615-2 · Cited by 1
Self-citationNot only as a Cullin3 ligase adaptor, SPOP may also act as a molecular bridge
Ge, Y., Kong, L., Li, Y., & Jin, X. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102189 · Cited by 1
Zhang, B., Zheng, J., Zhao, Y., Yu, Z., & Zheng, S. (2026) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001785 · Cited by 1
Park, S. K., Lee, J., Park, S. J., Kim, Y. N., Shin, G. H., Han, D., Choi, H., Han, D., Hwang, B. J., & Choi, M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523210123 · Cited by 1
Recent progress of PROTACs in cancer immunotherapy
Liu, P., Chen, Q., & Li, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110042 · Cited by 1
Zhou, Y., Lin, P., Wang, J., Huang, X., Zhang, H., Liu, J., Zhou, P., Liu, X. M., Chen, W., Sun, H., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108328 · Cited by 1
Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis
Fu, Y., Wang, Y., Wu, S., Ying, Y., Li, J. N., Ou, Y., Wang, Y., Li, L., Wu, Y., Yan, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775221 · Cited by 1
CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications
Türker, S. E., Demaria, M., & Wang, B. (2026) · Cancers · doi:10.3390/cancers18142192 · Cited by 1
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 1
Pan, J., Li, B., Lin, R., Fang, C., Lau, L., Hong, Z., & Chen, Y. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5932 · Cited by 1
Potential Movement of CDK 4/6 Inhibitor from Cell Cycle Arrest to Immune Activation in Breast Cancer
Satriyo, P. B. (2019) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2019.13.555855 · Cited by 1
Guo, J., Mu, D., Yu, W., Sun, L., Zhang, J., Ren, X., & Han, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.04 · Cited by 1
Self-citationTargeting Cyclin Dependent Kinase 4/6 for Cancer Therapy
Shi, S. (2023) · Transactions on Cancer · doi:10.23977/tranc.2023.040105 · Cited by 1
CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma
Zhu, S., Yang, H., Liu, L., Jiang, Z., Ji, J., Wang, X., Zhong, L., Liu, F., Gao, X., Wang, H., et al. (2023) · Journal of Bioinformatics and Systems Biology · doi:10.26502/jbsb.5107060 · Cited by 1
Self-citationKolyadina, I. V. (2024) · Tumors of female reproductive system · doi:10.17650/1994-4098-2024-20-1-89-103 · Cited by 1
Yan, S., Zhang, Z., Ji, J., Imam, M., & Wang, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189390 · Cited by 1
Checkpoint inhibitors in a marriage: consented or arranged?
Brest, P., Refae, S., Mograbi, B., Ferrero, J.-., Bontoux, C., Hofman, P. M., & Milano, G. A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01820-8 · Cited by 1
The Role of Immune Checkpoints in Cancer Progression
Prasetya, R. A., & Wulansari, D. D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105628 · Cited by 1
Mechanisms of PD-L1 Regulation in Tumor Immune Ecosystem
Bangash, F., Alia, S., & Gul, R. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1525 · Cited by 1
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., & El‐Deiry, W. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.20.347633 · Cited by 1
Cell fusion upregulates PD-L1 expression and promotes tumor formationPreprint
Tajima, Y., Shibasaki, F., & Masai, H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.14.496068 · Cited by 1
TRAF6 modulates PD-L1 expression through YAP1-TFCP2 signaling in melanomaPreprint
Liu, X., Wang, L., Han, Y., Tsai, H., Shu, F., Xu, Z., He, C., Zhu, H., Chen, H., & Cheng, F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.509909 · Cited by 1
CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter
Fan, Y., & Xu, B. (2023) · The Innovation Medicine · doi:10.59717/j.xinn-med.2023.100016 · Cited by 1
Andrieu, N., & Bendriss‐Vermare, N. (2018) · HAL · doi:10.1051/medsci/2018217
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G., & Sosman, J. (2019) · Cutaneous Melanoma · doi:10.1007/978-3-319-46029-1_55-1
Strategic Targeting of CENPE-PDL1 axis in NSCLCPreprint
Liang, J., Tian, C., Yang, Q., Gu, F., Pi, G., Liu, L., & Zhang, Y. (2020) · doi:10.21203/rs.3.rs-101164/v1
Shi, J., Cao, J., Lü, X., Fan, L.-L., Guo, H., & Fu, J. (2021) · Medical Science Monitor · doi:10.12659/msm.929199
Thavaneswaran, S., Sebastian, L. T., Kansara, M., Ballinger, M. L., Espinoza, D., Lin, F., Lee, C. K., Sjoquist, K. M., Grady, J. P., Cowley, M. J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-254137/v1
Current Progress in Cancer Immunotherapies Using Small Molecules Targeting PD-L1 Stability
Leung, M., Pipchuk, A., & Yang, X. (2021) · OBM Genetics · doi:10.21926/obm.genet.2101127
Effect of RB1 Loss on Breast Cancer Cell Invasion and Response to Experimental Therapy
Vorobieva, I. (2019) · TSpace (University of Toronto)
Sun, Y., Wang, J., Sun, X., Li, J., Zhao, X., Ma, Y., Shi, X., Qu, F., & Zhang, X. (2021) · Research Square · doi:10.21203/rs.3.rs-516399/v1
Self-citationUso de hormonas en fertilización
Parez, V. (1993) · Dialnet (Universidad de la Rioja)
Tumor Suppressor Gene SPOP in Prostate Cancer: A Review of Research Progress
马, 俊. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124410
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G. A., & Sosman, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_55
Congrès de l’association américaine de recherche contre le cancer — AACR 2018
Assoun, S., Benderra, M., Géraud, A., Bayle, A., Boilève, A., Soares, D. G., & Lotz, J. (2018) · ONCOLOGIE · doi:10.3166/onco-2018-0011
Huang, R., Zhu, J., Yang, R., Xiao, Y., Yan, J., Zheng, C., Xiao, W., Huang, C., & Wang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-488288/v1
RNF125 Modulates Tumor Immunity by Promoting Ubiquitination of PD-L1Preprint
Peng, Y., Yang, H., Li, Z., Li, H., Qiu, X., Wei, M., Chen, Z., Tang, Z., Wei, T., Wang, X., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-167238/v1
Self-citationEndicott, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737072659.793569640
Regulatory T Cells - New Insights
He, X. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.98075
Lin, C., Tsai, C.-L., Tang, Y., Chao, A., Yang, L., Wang, C., & Lai, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1887026/v1
Liu, Z., Cheng, X., Li, P., Liang, W., Zhu, Q., Zhang, J., Chang, H., & Gao, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2596907/v1
Self-citationShi, L., Yan, Y., He, Y., Yan, B., Pan, Y., Orme, J. J., Zhang, J., Xu, W., Pang, J., & Huang, H. (2023) · doi:10.1158/0008-5472.c.6513072.v1
Self-citationJing, W., Wang, G., Cui, Z., Xiong, G., Jiang, X., Li, Y., Li, W., Han, B., Chen, S., & Shi, B. (2023) · doi:10.1158/0008-5472.c.6513837.v1
Patnaik, A., Yap, T. A., Chung, H. C., Miguel, M. J. D., Bang, Y., Lin, C., Su, W., Italiano, A., Chow, K. H., Szpurka, A. M., et al. (2023) · doi:10.1158/1078-0432.c.6529953
Chen, Y., Cai, Q., Pan, C., Liu, W., Li, L., Liu, J., Gao, M., Li, X., Wang, L., Rao, Y., et al. (2023) · doi:10.1158/2326-6066.c.6550587
GABA/Baclofen Enhances Immunotherapy of Breast Cancer by Stabilizing PD-L1Preprint
Sun, X., Xu, Y., & Lv, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2767012/v1
Investigating the Intrinsic Role of Programmed Death-Ligand 1 in Human Cancers.
Hudson, K. (2023) · Sheffield Hallam University · doi:10.7190/shu-thesis-00520
Huang, H., Wu, J., Deng, X., Tu, X., Li, F., & Ke, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3236734/v1
Biomarkers determining treatment tactics in metastatic urothelial cancer
Grivtsova, L. Y., Karyakin, O. B., Syadrin, M. G., Samborsky, S. M., Иванов, С. А., & Каприн, А. Д. (2023) · Cancer Urology · doi:10.17650/1726-9776-2023-19-2-111-126
Nihira, N. T., Ohta, T., Liu, Z., & Dai, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1289016
Self-citationFeng, C., Li, Y., Zang, M., Jin-si-han, E.-E.-M.-B.-K., He, M., & Lu, Z. (2023) · Medical Science Monitor · doi:10.12659/msm.940556
Li, C., Hamon, Y., Mazaud, D., Troncoso, P. G., Dessard, M., He, H., Lamaze, C., & Blouin, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.15.571857
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735563
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
